載入...
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
BACKGROUND: Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib...
Na minha lista:
| 發表在: | BMC Pulm Med |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8293560/ https://ncbi.nlm.nih.gov/pubmed/34289823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-021-01598-0 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|